ATE361359T1 - Funktion und aktivität des viralen proteins r (vpr) - Google Patents

Funktion und aktivität des viralen proteins r (vpr)

Info

Publication number
ATE361359T1
ATE361359T1 AT94909839T AT94909839T ATE361359T1 AT E361359 T1 ATE361359 T1 AT E361359T1 AT 94909839 T AT94909839 T AT 94909839T AT 94909839 T AT94909839 T AT 94909839T AT E361359 T1 ATE361359 T1 AT E361359T1
Authority
AT
Austria
Prior art keywords
vpr
activity
disclosed
methods
identifying compounds
Prior art date
Application number
AT94909839T
Other languages
English (en)
Inventor
David B Weiner
David Nathan Levy
Yosef Refaeli
Original Assignee
David B Weiner
David Nathan Levy
Yosef Refaeli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/019,601 external-priority patent/US5874225A/en
Application filed by David B Weiner, David Nathan Levy, Yosef Refaeli filed Critical David B Weiner
Application granted granted Critical
Publication of ATE361359T1 publication Critical patent/ATE361359T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • AIDS & HIV (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
AT94909839T 1993-02-19 1994-02-22 Funktion und aktivität des viralen proteins r (vpr) ATE361359T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/019,601 US5874225A (en) 1993-02-19 1993-02-19 Identification of compounds that modulate HIV-1 vpr protein activity
US08/167,608 US6838236B1 (en) 1993-02-19 1993-12-15 VPR function and activity

Publications (1)

Publication Number Publication Date
ATE361359T1 true ATE361359T1 (de) 2007-05-15

Family

ID=26692390

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94909839T ATE361359T1 (de) 1993-02-19 1994-02-22 Funktion und aktivität des viralen proteins r (vpr)

Country Status (11)

Country Link
US (2) US20030207252A1 (de)
EP (1) EP0689586B8 (de)
AT (1) ATE361359T1 (de)
AU (1) AU6252494A (de)
CA (1) CA2155017C (de)
DE (1) DE69434961T2 (de)
DK (1) DK0689586T3 (de)
ES (1) ES2286818T3 (de)
IL (1) IL108707A (de)
MX (1) MXPA94001321A (de)
WO (1) WO1994019456A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2042093C (en) * 1990-05-09 2002-12-24 Gyula Hadlaczky Cell line carrying an excess of mammalian centromeres
CA2186398A1 (en) * 1994-03-25 1995-10-05 Ahmed A. Azad Vpr and vpx proteins of hiv
US5861161A (en) 1994-09-07 1999-01-19 Universite De Montreal Chimeric proteins comprising a Vpr/Vpx virion incorporation domain for targeting into HIV-1 or HIV-2 virions
US5763190A (en) 1994-09-21 1998-06-09 The Trustees Of The University Of Pennsylvania Methods for the identification of compounds capable of inducing the nuclear translocation of a receptor complex comprising the glucocoticoid receptor type II and viral protein R interacting protein
US5639619A (en) * 1994-10-13 1997-06-17 Regents Of The University Of California Screening assay for anti-HIV drugs using the Vpr gene
US6087486A (en) * 1996-01-29 2000-07-11 The Trustees Of The University Of Pennsylvania Nucleotide sequences encoding vpr receptor protein
US6077697A (en) 1996-04-10 2000-06-20 Chromos Molecular Systems, Inc. Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US6025155A (en) * 1996-04-10 2000-02-15 Chromos Molecular Systems, Inc. Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
WO1998035234A1 (en) * 1997-02-11 1998-08-13 The Regents Of The University Of California Identifying agents for treating lentiviral infection
US6818627B1 (en) 1997-08-14 2004-11-16 The Trustees Of The University Of Pennsylvania Functional fragments of HIV-1 Vpr protein and methods of using the same
US6984486B1 (en) 1999-02-19 2006-01-10 J. David Gladstone Institutes Synthetic peptide of regulatory virus protein R (VPR) of human immunodeficiency virus type 1 (HIV-1) and the utilization thereof
DE19908766C2 (de) * 1999-02-19 2001-02-15 Ulrich Schubert Verwendung synthetischer Vpr-Peptide des Humanen Immundefizienzvirus Typ 1 (HIV-1) zur Entwicklung von therapeutischen und diagnostischen Reagenzien
US6664040B2 (en) 2000-05-23 2003-12-16 The Regents Of The University Of California Compositions and methods for delivery of a molecule into a cell
WO2002100317A2 (en) 2001-05-25 2002-12-19 The Trustees Of The University Of Pennsylvania Targeted particles and methods of using the same
US7598041B2 (en) 2001-05-25 2009-10-06 The Trustees Of The University Of Pennsylvania HIV-1 VPR interactions with mitochondrial apoptosis inducing factor and methods of using the same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4808536A (en) * 1986-02-27 1989-02-28 Centocor, Inc. Immunochemical method for detection of antibody against HTLV-III core protein based upon recombinant HTLV-III gag gene encoded protein
EP0295803B1 (de) * 1987-05-29 1993-11-03 Shuzo Matsushita Monoklonale Antikörper
US5001230A (en) * 1988-02-18 1991-03-19 Schering Corporation T cell activation markers
ATE127520T1 (de) * 1989-06-02 1995-09-15 Dana Farber Cancer Inst Inc Protein mit transaktivierender eigenschaft, dieses protein exprimierende vektoren, zellinien und seine verwendungen.

Also Published As

Publication number Publication date
IL108707A (en) 1999-06-20
DE69434961D1 (de) 2007-06-14
EP0689586B1 (de) 2007-05-02
CA2155017C (en) 2009-06-09
ES2286818T3 (es) 2007-12-01
EP0689586A1 (de) 1996-01-03
MXPA94001321A (es) 2003-10-29
US20030207252A1 (en) 2003-11-06
WO1994019456A1 (en) 1994-09-01
IL108707A0 (en) 1994-05-30
DE69434961T2 (de) 2008-01-17
DK0689586T3 (da) 2007-08-06
EP0689586B8 (de) 2008-01-02
US20100183622A1 (en) 2010-07-22
EP0689586A4 (de) 1997-12-29
CA2155017A1 (en) 1994-09-01
AU6252494A (en) 1994-09-14

Similar Documents

Publication Publication Date Title
DE69434961D1 (de) Funktion und aktivität des viralen proteins r (vpr)
DE69738581D1 (de) Menschliche dnase i hyperaktive varianten
ES2005073A6 (es) Procedimiento para preparar benzamidas y bencenoacetamidas
NO962791L (no) Preparater inneholdende nukleinsyrer, deres fremstilling og anvendelse
RU95115239A (ru) Аналог эритропоэтина
EA200000723A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
DE69738754D1 (de) Hemmer der interaktion zwischen p53 und mdm2
HUP9800028A2 (hu) Több tumor esetében rendellenes sejtszaporodás előidézésében közrejátszó gének
HUP9901908A2 (hu) p16 Expressziós konstrukciók és alkalmazásuk rákterápiában
NO972391D0 (no) 2-substituerte 1,2,5-tiadiazolidin-3-on 1,1-dioksider og preparater og metoder for anvendelse derav
DK0750672T3 (da) DNA-sekvenser for matrix-metalproteaser, deres tilvejebringelse og anvendelse
ATE198354T1 (de) Protein aufspüren auf hiv virion auf basis von hiv-1 vpr fusionmolekulen
AU6745287A (en) Dna sequences coding for proteins having the biological activity of husi-type i inhibitors, biotechnological methods for the preparation of said proteins and pharmaceutical compositions containing said proteins
DE69132889D1 (de) Überlegende thrombomodulinanaloga zur pharmazeutischen verwendung
FI972170A7 (fi) Peptidejä, jotka kykenevät sitoutumaan GAP-proteiinin SH3-domeeniin, n äitä peptidejä koodittavia nukleotidisekvenssejä, niiden valmistus ja käyttö
EP0815240A4 (de) Neue menschliche proteine, die cyclinebhängigen kinasen ähneln, sowie methoden zu deren verwendung
ATE310828T1 (de) Implantat und vektor zur behandlung von erworbenen krankheiten
BG101846A (bg) Варианти на човешка дезоксирибонуклеаза i
ATE278011T1 (de) Human dnase ii
WO2023196880A3 (en) Human t-cell lymphotropic virus type 1 targeting proteins and methods of use
Cavalieri et al. Decreased Urinary Excretion of 2-Aminoethanol by Irradiated Human Beings
BG101847A (bg) Варианти на човешка дезоксирибонуклеаза i

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties